Pleiotropic effects of the β-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 45-52

  Wang, Ruijuan ^a   Miura, Toshiro ^a   Harada, Nozomu ^a   Kametani, Ryosuke ^a   Shibuya, Masaki ^a   Fukagawa, Yasuhiro ^a   Kawamura, Shuji ^a   Ikeda, Yasuhiro ^a   Hara, Masayuki ^b   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (PHENTOLAMINE); ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYSTEINE; HYDROGEN PEROXIDE; METOPROLOL; N ACETYL LEVO CYSTEINE; PHENTOLAMINE; PROPRANOLOL; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; APOPTOSIS; CALCIUM; CARBAZOLES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROPANOLAMINES; RATS; RATS, WISTAR;

EID: 33745237213     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.099903     Document Type: Article

References (23)

1. Abreu RM, Santos DJ, and Moreno AJ (2000) Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J Pharmacol Exp Ther 295:1022-1030.
2. Akao M, Rourke BO, Teshima Y, Seharaseyon J, and Marban E (2003) Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes. Circ Res 92:186-194.
3. de Groot AA, Mathy MJ, van Zwieten PA, and Peters SL (2004) Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 43:148-153.
4. Flesch M, Maack C, Cremers B, Baumer AT, Sudkamp M, and Bohm M (1999) Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100:346-353.
5. Giordano FJ (2005) Oxygen, oxidative stress, hypoxia and heart failure. J Clin Investig 115:500-508.
6. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, Utsumi H, Hamasaki N, and Takeshita A (2001) Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 88:529-535.
7. 2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun 328:116-124.
8. 2+ and voltage during anoxia/reoxygenation. Am J Physiol 280:C517-C526.
9. 2. J Mol Cell Cardiol 37:63-70.
10. MERIT-HF Study Group (1999) Effect of metoprolol CR=XL in chronic heart failure: Metoprolol CR=XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001-2007.
11. 1-adrenoceptors in human heart. Cardiovasc Res 69:128-139.
12. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, et al. (2002) Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871.
13. Okamura T, Miura T, Takemura G, Fujiwara H, Iwamoto H, Kawamura S, Kimura M, Ikeda Y, Iwatate M, and Matsuzaki M (2000) Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemia-reperfused rat heart. Cardiovasc Res 45:642-650.
14. Oliveira PJ, Marques MP, Batista de Carvalho LA, and Moreno AJ (2000) Effects of carvedilol on isolated heart mitochondria: evidence for a protonophoretic mechanism. Biochem Biophys Res Commun 276:82-87.
15. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7-13.
16. 2+] in cardiac cells. EMBO (Eur Mol Biol Organ) J 20:4998-5007.
17. Singal PK, Khaper N, Palace V, and Kumar D (1998) The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 40:426-432.
18. Skulachev VP (1998) Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett 423:275-280.
19. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, et al. (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846.
20. + exchange inhibitor, inhibits the mitochondrial death pathway. Circulation 108:2275-2281.
21. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, and Chien KR (1998) Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273:2161-2168.
22. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, and Feuerstein G (1992) Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92-98.
23. Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste G, Ruffolo RR Jr, et al. (1998) Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 82:166-174.